China HVT Safety, PK, PD

• Status: Completed
• Trial end date: 2015-02-17

Summary

This study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of denosumab administered subcutaneously to healthy adults in China.

• Phase: Phase 1

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Denosumab; Pharmaceutical Solutions